Bioprocess CDMO Institutional
10, Apr 2024
Biotimize’s R&D Center inauguration

In an unprecedented model in the country, Biotimize opens a laboratory to development of active biological inputs in Brazil Company is the first to work under GLP certification in Brazil to operate in the “as a service” model (CDMO) and will be the only one in South America to offer an end-to-end production service from… Continue reading Biotimize’s R&D Center inauguration

Bioprocess CDMO Institutional
05, Mar 2024
Good Laboratory Practice (GLP)

We are used to talk about Good Manufacturing Practice (GMP), however, have you thought the importance of the Good Laboratory Practice (GLP)? While GLP and GMP serve different purposes and address different stages of product development and manufacturing, they are both essential components of the regulatory framework governing the biopharmaceutical industry. GMP ensures the consistent… Continue reading Good Laboratory Practice (GLP)

03, Nov 2023
Partnership with PQE Group

We are pleased to announce that the development of our CDMO’s conceptual, basic and executive projects has begun! Last month we closed a partnership with PQE Group to develop the Conceptual, Basic and Executive projects of our CDMO. PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities… Continue reading Partnership with PQE Group

03, Oct 2023
Democratization of access to science and healing

The democratization of access to healing has been a transformative force in healthcare, aiming to ensure that quality medical services, medicines and treatments are accessible to a wider range of people around the world. And science plays an important role in this topic. The traditional model for developing biopharmaceutical products does not favor developing countries,… Continue reading Democratization of access to science and healing

05, Sep 2023
The Crucial Role of CDMOs in South America

Democratizing Access to Science: The Crucial Role of Contract Development and Manufacturing Organizations (CDMOs) in South America In the pursuit of global progress, the democratization of access to science stands as a pivotal objective. Contract Development and Manufacturing Organizations (CDMOs) have emerged as potent facilitators in this endeavor, playing a vital role in advancing scientific… Continue reading The Crucial Role of CDMOs in South America

01, Aug 2023
How to select the best CDMO for your needs?

In our last post, we talked about the CDMO importance (Why do we need a CDMO?). Now that it is clear, we need to understand what the key considerations are to choose the right CDMO for your process. Choosing a CDMO is something highly strategic and delicate, since the wrong choice can negatively impact the… Continue reading How to select the best CDMO for your needs?

29, Jun 2023
Why do we need a CDMO?

During the past decade, a significant shift has been seen in the nature of the products manufactured and sold by the innovative biopharmaceutical industry. The global biopharmaceutical portfolio of today contains a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise in treatments for many orphan… Continue reading Why do we need a CDMO?

30, May 2023
Biotimize’s New Era

In early 2023, we partnered with Sthorm to build the first CDMO for biopharmaceuticals in Brazil! Together we seek to develop new approaches to create a scenario where it is possible to democratize access to science and healing. That’s how we’re going to make a positive impact on people’s lives. With a new brand and a clear… Continue reading Biotimize’s New Era

30, May 2023
Biotimize in South Korea – GTH-B

The research, development and production of biological products has grown dramatically in recent years, and Brazil has accompanied this growth. To ensure the safety of these products, we need to implement quality rules that are standardized worldwide and recognized by our Health Surveillance Agency (ANVISA), and by international regulatory bodies. To ensure high quality research… Continue reading Biotimize in South Korea – GTH-B


Rigorous company in relation to the general data protection law (LGPD)

Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:

What are the data types? Personal data:
”Information related to the identified or viral person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.

Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.

What data does our Company collect? Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.

Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.

How do they use my data? The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.

Have you got any questions? Talk to the Data Protection Manager (DPO) by email:
You will be able to clarify doubts related to the processing of personal data.